Core Insights - Vivos Inc. and Exubrion Therapeutics have announced enhanced cooperation to advance targeted radioactive isotope technology for companion animals [1][2] - The collaboration will focus on shared clinic relationships, licensing coordination, and manufacturing optimization, building on previous efforts in device classification and clinician training [2] - Both companies aim to leverage their complementary strengths in treating different conditions in companion animals, with Vivos focusing on cancer therapy and Exubrion on osteoarthritis pain [3] Company Overview - Vivos Inc. is a radiotherapeutic company developing isotope-based products for cancer treatment and other therapeutic applications, including RadioGel for human use and IsoPet for veterinary applications [4] - Exubrion Therapeutics specializes in veterinary radiotherapeutics, with its lead product, Synovetin OA, targeting osteoarthritis in companion animals [5]

Core Insights - Vivos Inc. is advancing its human clinical trial for RadioGel Precision Radionuclide Therapy in India, which is designated as a Breakthrough Device by the FDA for treating solid tumors [1][10] Clinical Progress - The trial has successfully treated ten patients, confirming a strong safety profile and early evidence of efficacy, building on initial results that confirmed safety in the first five patients [2][3] - All patients have met the primary safety endpoint, with PET imaging showing precise retention of Yttrium-90 isotope at the injection site and no adverse events reported [3] - RadioGel has successfully treated tumors in high-risk anatomical regions without damaging adjacent critical tissues, demonstrating a high Therapeutic Ratio [4] Technical Innovations - The clinical team has implemented new technical refinements, including deep-needle injection techniques and precision image guidance, enhancing dose control and organ protection [6] - Ongoing discussions with Mayo Clinic investigators are aimed at preparing for a parallel clinical study in the U.S. [6] Expansion Plans - The study in India is approved to treat 30 patients, with a request being prepared to increase this to 50 patients to evaluate RadioGel in a broader range of tumor types [7] - Vivos is establishing a permanent operational presence in India, including plans for a corporate office and a regional manufacturing facility for yttrium phosphate microparticles [8] Market Opportunity - The cancer treatment market in India was valued at approximately USD 4.21 billion in 2023 and is projected to reach USD 5.89 billion by 2030, presenting a significant opportunity for innovative therapies like RadioGel [12] - Establishing a presence in India allows Vivos to diversify revenue streams and enhance global recognition of RadioGel as a relevant oncology solution [12] Regulatory Strategy - Vivos is sharing preliminary trial data with the FDA to support an Investigational Device Exemption (IDE) submission within the next 90 days [10] - The company is pursuing a multi-track global strategy to ensure momentum in regulatory progress, particularly in regions with streamlined pathways for innovative cancer therapies [10][11]